The Mann-Whitney test was performed for the data that did not follow normal distribution.
As regards the categorical variables, group differences were examined using the Chi-square test. The results were considered statistically significant when P<0.05. The statistical analyses were conducted with SPSS software (version 16). Results There were no differences between the EPO and control groups in terms of the number of impaired vessels (2.27±0.787 vs. 2.29±0.784; P=0.863) and age (59.73±7.73 vs. 62.57±8.6; P=1.878). Table 1 presents further information on the patients in the two groups. Table 1 Primary characteristics of the patients As is shown Inhibitors,research,lifescience,medical in table 2, there were no significantly differences between the Inhibitors,research,lifescience,medical EPO and control groups regarding the EF at 4 days after surgery (47.05±6.29 vs. 45.90±4.97; P=0.334) and also 30 days after surgery (47.27±28 vs. 46.62±5.7; P=0.69). Table 2 Patients’ EF before and after CABG in both groups The mean level of the wall motion score index (WMSI) also had no differences between the EPO and control groups at 4 days after surgery (1.08±0.09 vs. 1.07±0.10; P=0.83) and also 30 days after surgery
(1.10±0.13 vs. 1.10±0.16; P=0.902) (figure 2). The mean levels of left ventricular end-diastolic diameter (LVEDD) and left ventricular Inhibitors,research,lifescience,medical Lenalidomide price end-systolic diameter (LVESD) are shown in table 3. Figure 2 Wall motion score index before and after Ivacaftor solubility coronary artery bypass graft surgery in both groups. Table 3 Patients’ echocardiographic parameters in both groups S showed a significant rise at the 30th postoperative day in the EPO group (5.59+0.90 vs. 6.68+1.524; P=0.024), while it had a drop in the control group (6.33+1.11 vs. Inhibitors,research,lifescience,medical 5.61+1.07; P=0.015). Also, whereas E/A (1.02+0.83 Inhibitors,research,lifescience,medical vs. 0.95+0.28; P=0.717) and E/E’ (0.17+0.19 vs. 0.14+0.14; P=0.490) non-significantly decreased at
30 days after surgery in the EPO group, E/A (0.70+0.15 vs. 0.91+0.28; P=0.004) and E/E’ (0.10+0.03 vs. 0.12+0.04; P=0.188) significantly increased in the control group at 30 days after surgery. No important complications such as myocardial infarction, mean arterial pressure rise, and thromboembolic events were seen in the patients in the EPO group during surgery and in the first postoperative month. Discussion New articles have mentioned that the early post-CABG period is suboptimal for the estimation of the ventricular function due to perioperative ischemia and reperfusion injuries, which can negatively affect AV-951 the contractile function.22 The present study evaluated the effect of a single bolus of EPO on the first 4 weeks after CABG. The LV function is usually described in terms of the EF.23 In the present study, there were no significant differences between the EPO and control groups with respect to the EF at 4 days and also 30 days after surgery, which means that EPO had no effect on improving the ventricular function in the first 4 weeks following CABG.